- Tablets 0.25 mg
- Tablets 0.125 mg
- Tablets 0.25 mg
Potentiates action of GABA, an inhibitory neurotransmitter, resulting in increased neuronal inhibition and CNS depression, especially in limbic system and reticular formation.
Triazolam's T max is 2 h; C max is 1 to 6 ng/mL. Plasma levels achieved are proportional to the dose given.
Metabolites are mainly conjugated glucuronides presumably inactive.
Triazolam plasma t ½ is 1.5 to 5.5 h. Metabolites are primarily excreted in urine (79.9%). Urinary excretion is biphasic in its time course.
Indications and Usage
Treatment of insomnia.
Hypersensitivity to benzodiazepines; pregnancy.
Dosage and AdministrationAdults
PO 0.125 to 0.5 mg at bedtime.Elderly or debilitated patients
Initiate with 0.125 mg until individual response is determined.
Store at room temperature in a tight, light-resistant container.
Drug InteractionsAlcohol, CNS depressants (eg, narcotic sedatives)
May cause additive CNS depressant effects.Cimetidine, disulfiram, omeprazole, oral contraceptives
Triazolam effects may increase.Digoxin
Serum digoxin concentrations may be increased.Theophylline
May antagonize sedative effects.
Laboratory Test Interactions
None well documented.
Anterograde amnesia; headache; nervousness; drowsiness; confusion; talkativeness; apprehension; irritability; euphoria; weakness; tremor; incoordination; memory impairment; depression; ataxia; dizziness; dreaming/nightmares; hallucinations; paradoxical reactions (eg, anger, hostility, mania, muscle spasms).
Visual or auditory disturbances; depressed hearing; taste disturbances.
Heartburn; nausea; vomiting; diarrhea; constipation; dry mouth; anorexia.
Blood dyscrasias including agranulocytosis; anemia; thrombocytopenia; leukopenia; neutropenia.
Hepatic dysfunction including hepatitis and jaundice.
Dependence/withdrawal syndrome (eg, confusion, abnormal perception of movement, depersonalization, muscle twitching, psychosis, paranoid delusions, seizures). Rebound sleep disorder (recurrence of insomnia worse than before treatment) may occur during first 3 nights after abrupt discontinuation.
Category X .
Not for use in children younger than 18 yr of age.
Special Risk Patients
Use drug with caution in elderly patients and patients with renal or hepatic function impairment, depression or suicidal tendencies, drug abuse and dependence, chronic pulmonary insufficiency or apnea, seizure disorder.
Prolonged use (more than 1 to 2 wk) can lead to dependence. Withdrawal syndrome may occur; taper dose gradually.
Somnolence, confusion, delirium, lack of coordination, ataxia, slurred speech, respiratory depression, coma, seizures.
- Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
- Remind patient that medication should not be abruptly discontinued.
- Review with patient and family other general sleep promotion measures, as well as what to avoid, such as caffeine and excessive exercise at bedtime.
- Explain that medication may cause morning drowsiness or tiredness.
- Caution patient regarding dependence potential.
- Explain potential side effects and what to report to health care provider (eg, confusion, paradoxical excitement, headache, bleeding, recurrent sleep disorder).
- Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
- Advise patient to use caution while driving or performing other tasks requiring mental alertness.
Copyright © 2009 Wolters Kluwer Health.